Core Insights - Baird Medical is preparing for market entry by establishing partnerships with leading healthcare institutions to create distribution networks and training programs for microwave ablation (MWA) procedures [1][2] - The company specializes in minimally invasive procedures, particularly MWA, which utilizes targeted microwave energy for high precision and efficiency in treating thyroid nodules and tumors [2][3] - Baird Medical is committed to integrating AI-powered surgical robotic systems and innovative instruments into its offerings, aiming to enhance patient outcomes through advanced technology [3] Company Overview - Baird Medical focuses on minimally invasive diagnostics and treatments, with a mission to improve patient outcomes through precision technology [3] - The company is FDA 510(k)-certified and has deployed its solutions in over 30 prestigious hospitals and clinics in the United States, including Johns Hopkins Hospital and Weill Cornell Medicine [3] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [3]

Core Insights - Baird Medical has received the "Most Valuable Investment Award" for its AI Tumor Ablation Surgical Robot at the 10th China Medical Industry Innovation Competition, highlighting its advancements in AI and robotics in the medical field [1][7] AI & Robotics Integration - The AI Tumor Ablation Surgical Robot integrates multimodal AI algorithms with high-precision robotic arm control, offering significant technological advantages [2] - Key innovations include autonomous decision-making, multi-technology synergy, and end-to-end intelligent automation, enhancing surgical efficiency and precision [5] Research & Development Strategy - Baird Medical's R&D strategy focuses on "Global Expertise + Local Innovation," supported by a world-class team and cutting-edge development [3] - The company has established a comprehensive validation framework through multi-center clinical simulations across 20 top-tier hospitals [5] Expanding Applications - The robotic system is designed for precise ablation of various solid tumors and chronic pain management, with potential applications in neurosurgery and urology [4] - Its modular design allows for rapid adaptation to different surgical needs, marking a significant advancement in minimally invasive surgery [4] Future Prospects - The commercialization of the AI-powered surgical robot is expected to initiate regulatory approvals and market expansion across more than 30 countries, positioning Baird Medical at the forefront of intelligent healthcare [6][7] - The company aims to transform minimally invasive surgery from an experience-based practice to a data-driven discipline, leveraging deep learning technologies [6][7] Company Overview - Baird Medical specializes in minimally invasive diagnostics and treatment, focusing on AI-powered surgical robotic systems and innovative surgical instruments [8] - The company is FDA 510(k)-certified and has deployed solutions in over 30 prestigious hospitals in the U.S., while also being a market leader in China for thyroid microwave ablation devices [8]

Core Insights - Baird Medical has received regulatory approval to expand its operations in Indonesia, emphasizing its commitment to enhancing patient care through innovative, minimally invasive technologies [1][3] - The company specializes in microwave ablation (MWA), a precise and effective procedure for treating conditions like thyroid nodules and tumors, known for its minimal impact on surrounding tissues and faster recovery times [2][4] - Baird Medical aims to strengthen its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its strategy to introduce next-generation medical solutions to emerging markets [3][4] Company Overview - Baird Medical is a medical device company focused on minimally invasive diagnostics and treatments, dedicated to the research and development of AI-powered surgical robotic systems and innovative surgical instruments [4] - The company has deployed its solutions in over 30 prestigious hospitals and clinics in the United States, including renowned institutions like Johns Hopkins Hospital and Weill Cornell Medicine [4] - Baird Medical is a market leader in China for thyroid microwave ablation devices and is expanding its commercial presence in over 20 countries worldwide [4]

As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences. Baird Medical's presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in ha ...

Core Insights - The training program for the delegation focused on enhancing expertise in microwave ablation (MWA) techniques, featuring both theoretical discussions and hands-on demonstrations [1][2] - Baird Medical emphasizes its commitment to global knowledge-sharing and medical innovation, aiming to advance MWA technology and improve patient care worldwide [3] - Baird Medical is a publicly traded company on NASDAQ, specializing in minimally invasive MWA technology for various medical conditions [4] Training Program Details - The first day of the program included theoretical discussions and hands-on demonstrations at Baird Medical's facility, providing a deeper understanding of MWA applications [1] - On the second day, the delegation observed live MWA procedures at Sun Yat-sen University Cancer Center and engaged in discussions with leading specialists [2] - The program concluded with an in-depth session on thyroid microwave ablation techniques, enhancing the participants' knowledge of the latest advancements in MWA technology [2] Company Overview - Baird Medical is a leader in providing advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer through MWA technology [4] - The company is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices [4]

Core Insights - The article highlights a two-day training course on microwave ablation (MWA) techniques led by Dr. Jennifer Kuo, aimed at enhancing procedural safety and clinical applications for physicians from the U.S. and Mexico [1][4]. Group 1: Training Program - The training included hands-on sessions where participants, such as Dr. Hesham, practiced simulated procedures to improve their skills in thyroid MWA, focusing on device operation and ablation precision [2]. - A live case observation session allowed physicians to gain insights into MWA's preoperative planning, intraoperative techniques, and postoperative management, with positive feedback on the practical nature of the training [3]. Group 2: Company Overview - Baird Medical is a leading provider of minimally invasive MWA technology, addressing conditions like thyroid nodules, breast disease, uterine fibroids, and liver cancer, and is publicly traded on NASDAQ [5]. - The company is committed to accelerating the adoption of innovative treatments through specialized training and aims to enhance procedural expertise among physicians globally [4].

Core Insights - Baird Medical showcased its minimally invasive microwave ablation (MWA) technology at NASIT 2025, generating significant interest and discussions among clinicians regarding future thyroid therapies [1][3] - Dr. Emad Kandil presented compelling case studies highlighting MWA as a safe and effective alternative to traditional thyroid surgery, emphasizing benefits such as reduced procedure times and improved patient outcomes [2] - The company aims to enhance treatment options through further research and strategic partnerships, reinforcing its commitment to innovation in patient care [3][4] Company Overview - Baird Medical is a leading provider of minimally invasive MWA technology, focusing on advanced treatment solutions for conditions like thyroid nodules, breast disease, uterine fibroids, and liver cancer [4] - The company is publicly traded on NASDAQ and is dedicated to improving patient care through precision, efficiency, and safety in its medical devices [4]

Core Insights - The 2025 Microcap Conference served as a significant platform for Baird Medical to showcase its technological advancements and explore strategic opportunities in the industry [1][2][4] Company Highlights - Baird Medical presented its minimally invasive microwave ablation technology, emphasizing its leadership in research and development [2][4] - The company shared its global expansion strategy following the recent FDA 510(k) clearance for the U.S. market, indicating readiness for market penetration [2][3] Strategic Initiatives - Baird Medical's leadership engaged in one-on-one meetings with investors to discuss growth plans, market penetration strategies, and product promotion initiatives in the U.S. [3] - Extensive discussions were held regarding potential mergers and acquisitions, focusing on resource integration, technological synergies, and market collaboration [3][4] Future Outlook - The company aims to leverage insights and partnerships from the conference to enhance global market expansion and improve patient outcomes through innovative technologies [4] - Baird Medical plans to continue investing in research and development to enhance product quality and performance while actively exploring merger and acquisition opportunities [4] Company Background - Baird Medical is a leading provider of minimally invasive microwave ablation technology, addressing conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer [5] - The company is publicly traded on NASDAQ and is committed to enhancing patient care through precision, efficiency, and safety in its medical devices [5]

On October 2, 2024 (U.S. Eastern Time), Baird Medical successfully listed on the Nasdaq Stock Market, marking a significant milestone in its international growth strategy. This listing reinforces the Company's commitment to innovation, global market expansion, and enhancing shareholder value as it continues to pioneer cutting-edge medical solutions. PatentsIn 2024, Baird Medical further expanded its intellectual property portfolio, securing patents that enhance MWA technology and production efficiency: Inve ...

The NASIT Conference is a premier forum for education, research, and collaboration in thyroid interventions, and Baird Medical is honored to participate in this key industry event. The Company's invitation highlights its growing prominence in the field of microwave ablation while offering a valuable opportunity to engage with global experts, industry leaders, and potential partners. As a returning participant, Baird Medical is excited to contribute to discussions on the latest advancements in MWA technology ...